Drug Trial Radar · NCT03122262
ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy
Last checked: Nov 19, 2026Latest source record: Feb 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,110
Actual
Start
Jan 16, 2017
Primary completion
Apr 30, 2022
Study completion Jul 29, 2022
Sponsor
- Lead sponsor
- Professor Francois VenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a non-inferiority (10% non-inferiority margin), study to assess the efficacy and safety of dolutegravir, DTG (50 mg once daily \[QD\]) administered in combination with tenofovir alafenamide fumarate, TAF (25 mg QD) and emtricitabine, FTC (200 mg QD) compared to DTG (50 mg QD) administered in combination with tenofovir disoproxil fumarate, TDF (300 mg QD) and FTC (200 mg QD) and compared to efavirenz, EFV (600 mg QD) administered in combination with TDF (300 mg QD) and FTC (200 mg QD) through 96 weeks in patients with HIV-1 starting first-line ART.
Conditions
- HIV-1 Infection
Interventions
DolutegravirDrug
DTG 50mg Oral Tablet once daily
Tenofovir AlafenamideDrug
TAF/FTC 25/200mg Oral Tablet once daily
TruvadaDrug
AtriplaDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with undetectable plasma HIV-1 RNA levels (< 50 copies/mL) at Week 48Time frame: 48 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Shandukani Research Centre
Johannesburg, Gauteng, South Africa
Charlotte Maxeke Johannesburg Academic Hospital
Johannesburg, Gauteng, South Africa
Sunnyside Office Park
Johannesburg, Gauteng, South Africa
Wits RHI Yeoville Clinic
Johannesburg, Gauteng, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.